Citi maintained a Buy rating on Ambit Biosciences (NASDAQ: AMBI) and lowered its price target to $17.00 (from $19.00). The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE